{"id":"W4386021670","doi":"10.1097/01.hs9.0000967980.32472.94","title":"S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Dosing; Pharmacokinetics; Pharmacodynamics; Adverse effect; Clinical trial; Internal medicine; Pediatrics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001701274,0.0004880848,0.001126776,0.0002647018,0.0002267597,0.0006923203,0.0003769744,0.000600707,0.001739337],"category_scores_gemma":[0.001540071,0.0002791188,0.001182436,0.0003550641,0.0002102198,0.0004774814,0.0002450536,0.0009672283,0.0006525565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003984029,"about_ca_system_score_gemma":0.0007045265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008270986,"about_ca_topic_score_gemma":0.001243592,"domain_scores_codex":[0.9993561,0.0002104733,0.00006687937,0.0001299007,0.0001777928,0.0000590007],"domain_scores_gemma":[0.9984332,0.0002772449,0.0007069923,0.00009395883,0.0001792763,0.0003093814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1972717,0.004439525,0.6335779,0.001439174,0.004682178,0.001202984,0.000467402,0.003679794,0.03639187,0.0002495493,0.01400656,0.1025913],"study_design_scores_gemma":[0.03653267,0.0887906,0.8396639,0.0002134083,0.002396026,0.003687804,0.0001887111,0.004097736,0.009011207,0.0002242114,0.01506065,0.0001331049],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887841,0.005106739,0.0002763991,0.0002091264,0.00002425068,0.0001210151,0.004492848,0.00003622173,0.0009493702],"genre_scores_gemma":[0.9870757,0.001602442,0.0006283201,0.0003445825,0.00008721135,0.0001509184,0.00913169,0.00002205738,0.0009570509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001739337,"threshold_uncertainty_score":0.008997321,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01948532737350761,"score_gpt":0.2944407052088396,"score_spread":0.274955377835332,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}